SALT LAKE CITY — In this video, Jay Chhablani, MD, professor of ophthalmology at University of Pittsburgh School of Medicine, discusses a preliminary study of combination gene therapy targeting neovascular age-related macular degeneration.
The therapy, a combination of AIBP, apoA-I and aflibercept, showed promise in a mouse study presented at the ARVO meeting, Chhablani said.
“This combination of this triple gene therapy may overcome the anti-VEGF resistance as well as improve outcomes,” Chhablani said.